Evofem’s non-hormonal contraceptive Amphora scores attractive added benefit for bacterial infection prevention

GlobalData believes that the favourable data demonstrated in the AMPREVENCE trial will drive broader use of Amphora and provide a new market opportunity for the product with the added benefit of preventing sexually transmitted infections (STIs).

On 2 December Evofem Biosciences announced positive top-line results from the Phase IIb AMPREVENCE trial evaluating the efficacy and safety of its lead candidate Amphora for the prevention of urogenital chlamydia and gonorrhoea in women.

The study met both its primary and secondary endpoints of reducing the risk of chlamydia and gonorrhoea infection, respectively, with the company’s stock price rising more than 25% upon the announcement.

Amphora, a multipurpose vaginal gel pH regulator, is also being developed as a female contraceptive. GlobalData believes that the favourable data demonstrated in the AMPREVENCE trial will drive broader use of Amphora and provide a new market opportunity for the product with the added benefit of preventing sexually transmitted infections (STIs).

Key opinion leaders (KOLs) interviewed by GlobalData viewed Amphora’s efficacy as a contraceptive questionable when used as the sole method but further opined that Amphora’s potential role in protecting women from the infection will make it an attractive product for women at risk of contracting STIs.

Amphora can be an appealing option for women seeking a non-hormonal contraceptive, who are willing to accept a higher chance of unintended pregnancy compared to the hormonal options while benefiting from increased protection against STIs, especially when healthcare access may be limited.

Amphora has the advantage of fewer side effects compared to hormonal contraceptives. However, it also demonstrates lower efficacy than hormonal contraception (89.5% and 95.9% contraceptive efficacy with typical and perfect use, respectively). Although there is an unmet need for non-hormonal contraceptives for women of reproductive age, Amphora may only partially fulfil this need because of its low efficacy profile and the expected need for an additional barrier.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Tick here to opt out of curated industry news, reports, and event updates from Clinical Trials Arena.

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Non-hormonal contraceptives offer another option for women who want to avoid the side effects of hormonal contraceptives. Following a complete response letter (CRL) from the Food and Drug Administration (FDA) in 2016, Evofem resubmitted a New Drug Application (NDA) last month, based on positive data from AMPOWER and prior results from the earlier AMP001 trial, seeking approval for the prevention of pregnancy.

GlobalData (2019) Female Infertility: Opportunity Analysis and Forecasts to 2028